Daily Respiratory Research Analysis
Analyzed 191 papers and selected 3 impactful papers.
Summary
Analyzed 191 papers and selected 3 impactful articles.
Selected Articles
1. Mucosal tissue cues shape B cell memory through the IgA BCR.
Using respiratory and gastrointestinal infection models in mice, the authors show that tissue-specific cues bias B cell fates: the lung favors memory B cells while the gut favors plasma cell entry, driven by BCR isotype usage rather than affinity maturation. A TGF-β-rich milieu promotes IgA class switching and plasma cell skewing, partially counteracted by the IgA cytosolic tail domain, informing strategies for intranasal and oral vaccines.
Impact: This mechanistic study reframes mucosal B cell memory as an isotype- and tissue cue-driven process, challenging affinity-centric paradigms and directly informing mucosal vaccine design.
Clinical Implications: Guides the rational design of intranasal/oral vaccines by leveraging tissue microenvironments to bias durable memory versus effector responses; suggests modulating IgA switching and signaling to optimize protective immunity in the respiratory tract.
Key Findings
- Lung memory selection skews toward memory B cells, whereas the gut favors plasma cell entry even to the same pathogen.
- Divergence is linked to BCR isotype usage (not affinity maturation); a TGF-β-rich milieu promotes IgA class switching in the gut.
- The IgA cytosolic tail domain counteracts plasma cell skewing, indicating intracellular signaling control of fate decisions.
Methodological Strengths
- In vivo respiratory and gastrointestinal infection models with tissue-resolved analyses
- Mechanistic dissection linking isotype usage, local cytokine milieu (TGF-β), and receptor tail signaling
Limitations
- Findings are in murine models; human validation across airway and gut tissues is needed
- Specific pathogens and exposure contexts may differentially modulate isotype-driven selection
Future Directions: Validate tissue cue–isotype mechanisms in human mucosa; test adjuvants and delivery platforms that tune IgA switching and BCR tail signaling to enhance respiratory mucosal vaccines.
B cells generate plasma cells (PCs) and memory B cells (MBCs) to combat recurrent pathogens. B cell receptor (BCR) affinity dictates fate decisions in response to model antigens, but the factors regulating B cell fate during infection remain unknown. Here, we used respiratory and gastrointestinal infection models to study B cell selection across barrier tissues in mice. Memory selection was governed by tissue-specific cues: Selection in the lung was skewed toward MBCs, whereas the gut favored PC entry, even in response to the same pathogen. Divergence was linked to differential BCR isotype usage across barrier tissues rather than differential affinity maturation. In the gut, the commensal-induced TGF-β-rich milieu promoted class-switching to IgA, which skewed selection toward PCs, a process that was counteracted by the IgA cytosolic tail domain. Thus, mucosal B cell selection integrates tissue-specific cues by relying on BCR isotype usage, with implications for nasal and oral vaccine development.
2. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.
In a double-blind randomized trial of 144 non-hospitalized adults with acute COVID-19, 5 days of nirmatrelvir-ritonavir reduced 3-month post-COVID symptom prevalence versus placebo (26% vs 43%; relative risk 0.60, 95% CI 0.37–0.98). No severe adverse events occurred; dysgeusia and nausea were more frequent with active therapy. Early termination limited power but the signal supports larger confirmatory trials.
Impact: This is among the first blinded RCTs to prospectively test an antiviral’s effect on long COVID, suggesting a preventive strategy with immediate translational implications.
Clinical Implications: Clinicians may consider that early antiviral therapy could reduce post-acute sequelae risk in lower-risk outpatients, while awaiting larger confirmatory trials and longer follow-up to inform guidelines.
Key Findings
- Double-blind, randomized, placebo-controlled outpatient trial (n=144) of nirmatrelvir-ritonavir within 5 days of symptom onset.
- Lower 3-month long COVID prevalence with nirmatrelvir-ritonavir vs placebo (26% vs 43%; relative risk 0.60, 95% CI 0.37–0.98; p=0.039).
- No severe adverse events; dysgeusia (86% vs 18%) and nausea/vomiting (29% vs 10%) were more frequent with active therapy; five discontinuations due to adverse events.
Methodological Strengths
- Double-blind, randomized, placebo-controlled multicenter design with intention-to-treat analysis.
- Prospectively defined patient-reported long COVID outcome at 3 months.
Limitations
- Early termination with small sample size limited statistical power and precision.
- Short follow-up (3 months) and exclusion of higher-risk populations limit generalizability.
Future Directions: Larger, adequately powered RCTs with longer follow-up, diverse populations, and mechanistic endpoints (e.g., viral kinetics, immune signatures) are needed to confirm prevention of post-COVID condition.
BACKGROUND: Long-term symptoms are common after acute COVID-19, particularly fatigue, cognitive problems, and dyspnoea. Cohort studies have suggested that antiviral treatment of acute COVID-19 might prevent development of post-COVID-19 condition (also known as long COVID), but the efficacy of antivirals has yet to be verified in prospective studies. We aimed to investigate whether treatment of acute SARS-CoV-2 infection with nirmatrelvir-ritonavir would reduce the risk of long COVID. METHODS: In this double-blind, randomised, placebo-controlled trial, participants were recruited from the municipal health-care service at three sites in Norway (Bergen, Oslo, and Ålesund). Non-hospitalised adults aged 18-65 years with SARS-CoV-2 infection confirmed by PCR or lateral flow test and symptoms for 5 days or fewer were eligible for inclusion. Key exclusion criteria included pregnancy or lactation, chronic renal impairment or chronic liver dysfunction, and any person judged by the investigator to need nirmatrelvir-ritonavir treatment due to increased risk of hospitalisation or death. Participants were allocated in a 1:1 ratio to receive oral 300 mg nirmatrelvir and 100 mg ritonavir, or placebo, twice a day for 5 days using a pre-generated randomisation list without stratification or block adjustment. Participants, clinicians, and the study team were masked to treatment allocation. The primary outcome was long COVID, defined as patient-reported fatigue, dyspnoea, and/or cognitive symptoms at 3 months' follow-up. Safety was analysed as a secondary outcome, and included adverse events, hospital admissions, and deaths. Both the primary outcome and safety were assessed in the intention-to-treat population. The trial is registered with ClinicalTrials.gov (NCT05852873) and is now closed to new participants. FINDINGS: Between May 12, 2023, and June 11, 2025, we enrolled 144 participants, of whom 66 were assigned to nirmatrelvir-ritonavir and 78 to placebo. In the protocol we planned to enrol 2000 participants, but the trial was stopped prematurely by the steering committee due to insufficient recruitment. Among the 143 participants who completed follow-up, the risk of long COVID at 3 months was significantly reduced in the nirmatrelvir-ritonavir group (17 [26%] of 66) compared with the placebo group (33 [43%] of 77), corresponding to a relative risk after imputation of data for the single missing value in the placebo group of 0·60 (95% CI 0·37-0·98; p=0·039). In the nirmatrelvir-ritonavir group, five patients discontinued treatment due to adverse events. The most common adverse events in the nirmatrelvir-ritonavir group were change in taste or smell (57 [86%] of 66 in the nirmatrelvir-ritonavir group vs 14 [18%] of 78 in the placebo group) and nausea or vomiting (19 [29%] vs eight [10%]). Inversely, palpitations were more common in the placebo group (ten [13%] of 78) than in the nirmatrelvir-ritonavir group (two [3%] of 66). No severe adverse events were reported. INTERPRETATION: Treatment with nirmatrelvir-ritonavir for acute COVID-19 was associated with a significant reduction in the risk of long COVID at 3 months' follow-up. The limited sample size precludes firm conclusions, and further clinical trials are warranted. FUNDING: National Health Authorities' KlinBeForsk programme, Western Norway Regional Health Authority, Helse Møre og Romsdal Hospital Trust, and The Influenza Centre, Haukeland University Hospital and University of Bergen, Bergen, Norway.
3. Triple IFN pathway deficiency sensitizes mice to human respiratory virus infection independent of human viral receptor expression.
The authors created AGL mice lacking type I, II, and III interferon receptors, rendering them susceptible to diverse human respiratory viruses without human receptor expression. Type III IFN served as a backup antiviral layer, and antiviral proof-of-concept studies in MPXV and PIV underscore the model’s translational value.
Impact: This work provides a universal small-animal platform to study human respiratory viruses and to test antivirals without engineering human receptors, potentially accelerating pathogen research and countermeasure development.
Clinical Implications: While preclinical, the AGL model can prioritize antiviral candidates and elucidate host–virus interactions across DNA and RNA respiratory pathogens, informing translational pipelines and pandemic preparedness.
Key Findings
- Generated triple IFN receptor knockout (IFNAR, IFNGR, IFNLR) mice (AGL) with severe innate immunity deficiency.
- AGL mice were susceptible to multiple human respiratory viruses (HAdV-55, MPXV clade IIb, PIV, SARS-CoV-2 Delta) without human receptor expression.
- Type III IFN provides a secondary antiviral barrier beneath type I/II pathways; antiviral proof-of-concept tests in MPXV and PIV demonstrate translational utility.
Methodological Strengths
- Cross-viral family testing across DNA and RNA respiratory pathogens in vivo.
- Functional proof-of-concept antiviral interventions highlighting translational relevance.
Limitations
- Preclinical murine model; species-specific immune and pathophysiologic differences may limit direct human translation.
- Mechanistic dissection of receptor-independent entry across all tested viruses was limited.
Future Directions: Use AGL mice to benchmark antiviral classes, map host–virus interactions, and evaluate vaccine and immunotherapy strategies across pathogens, integrating omics to resolve IFN-axis compensatory mechanisms.
Interferon (IFN) pathways form the innate barrier against viral invasion and partial deficiency in these pathways allows human virus infection. Whether a complete IFN pathway deficiency could confer the susceptibility to human viral infection independent of expressing the human viral receptor remains unknown. We develop an innate immunity severely deficient mouse model, designated AGL, which features one-step knock-out of the IFNAR, IFNGR and IFNLR. The AGL mice become susceptible to diverse representative human respiratory viruses, including adenovirus type 55 (HAdV-55; double-stranded DNA), human monkeypox virus (MPXV) clade IIb (double-stranded DNA), parainfluenza virus (PIV; negative-sense single-stranded RNA), and the clinically isolated SARS-CoV-2 delta variant (positive-sense single-stranded RNA). Our results suggest that the type III IFN pathway constitutes a backup layer of antiviral frontline beneath the type I and II IFN pathways. In addition, proof-of-concept studies testing MPXV and PIV antivirals highlight the translational value of AGL mice. The AGL mice, as a universal model, substantially enhance the ability to investigate both emerging and established viruses without the need for tailored mouse models.